Secondary HIV Infection and Mitigation in Cure-Related HIV Trials During Analytical Treatment Interruptions
J Infect Dis
.
2019 Aug 30;220(7):1230-1231.
doi: 10.1093/infdis/jiz262.
Authors
Lynda Dee
1
,
Cheriko A Boone
2
3
,
David Palm
4
5
,
Danielle Campbell
6
,
Karine Dubé
7
Affiliations
1
Delaney AIDS Research Enterprise Community Advisory Board, AIDS Action, Baltimore, Maryland.
2
Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication Community Advisory Board, New York, New York.
3
George Washington University, Department of Psychology, Washington, District of Columbia.
4
Global HIV Prevention and Treatment Unit Clinical Trials Community Advisory Board, Chapel Hill, North Carolina.
5
Collaboratory of AIDS Researchers for Eradication Community Advisory Board, Chapel Hill, North Carolina.
6
Delaney AIDS Research Enterprise Community Advisory Board, Los Angeles, California.
7
University of North Carolina Gillings School of Global Public Health, Chapel Hill.
PMID:
31505661
PMCID:
PMC7325328
DOI:
10.1093/infdis/jiz262
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Comment
MeSH terms
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Coinfection*
HIV Infections*
HIV-1*
Humans
Grants and funding
R21 MH118120/MH/NIMH NIH HHS/United States